• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

蛛网膜下腔出血和择期神经外科手术后的肠道药物吸收:埃索美拉唑药代动力学的启示

Intestinal Drug Absorption After Subarachnoid Hemorrhage and Elective Neurosurgery: Insights From Esomeprazole Pharmacokinetics.

作者信息

Kranawetter Beate, Brockmöller Jürgen, Sindern Juliane, Hapke Anne, Bruns Ellen, Harnisch Lars-Olav, Moerer Onnen, Stenzig Justus, Mielke Dorothee, Rohde Veit, Abboud Tammam

机构信息

Department of Neurosurgery, University Medical Center Göttingen, Göttingen, Germany.

Institute of Clinical Pharmacology, University Medical Center Göttingen, Göttingen, Germany.

出版信息

Crit Care Med. 2025 Jan 1;53(1):e140-e150. doi: 10.1097/CCM.0000000000006512. Epub 2024 Nov 20.

DOI:10.1097/CCM.0000000000006512
PMID:39570079
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11698135/
Abstract

OBJECTIVES

Subarachnoid hemorrhage (SAH) may critically impair cardiovascular, metabolic, and gastrointestinal function. Previous research has demonstrated compromised drug absorption in this group of patients. This study aimed to examine the impact of SAH on gastrointestinal function and its subsequent effect on the absorption of enterally administered drugs, using esomeprazole as a probe drug.

DESIGN

Prospective observational cohort study.

SETTING

Academic hospital in Germany.

PATIENTS

We included 17 patients with high-grade SAH and 17 controls, comparable in age, sex, body weight, and renal function, who underwent elective cranial surgery.

INTERVENTIONS

None.

MEASUREMENTS AND MAIN RESULTS

Both groups received esomeprazole per standard protocol to prevent acid-associated mucosal damage, either orally or through a nasogastric tube. On day 4, esomeprazole was administered IV to estimate oral bioavailability. Esomeprazole serum concentrations were measured on days 1, 3, and 4 in both groups and on day 7 in the SAH group. Patients with high-grade SAH exhibited severely impaired drug absorption. Most patients showed no improvement in intestinal drug absorption even a week after hemorrhage.

CONCLUSIONS

Following SAH, significantly reduced drug absorption may be attributed to decreased intestinal motility and compromised intestinal mucosal function. Clinicians should anticipate the reduced effectiveness of enterally administered medications for at least seven days after high-grade SAH.

摘要

目的

蛛网膜下腔出血(SAH)可能严重损害心血管、代谢及胃肠功能。既往研究表明该组患者药物吸收受损。本研究旨在以埃索美拉唑作为受试药物,探讨SAH对胃肠功能的影响及其对肠内给药药物吸收的后续作用。

设计

前瞻性观察性队列研究。

地点

德国的一家学术医院。

患者

我们纳入了17例重度SAH患者和17名对照者,他们在年龄、性别、体重和肾功能方面具有可比性,均接受择期开颅手术。

干预措施

无。

测量指标及主要结果

两组均按照标准方案接受埃索美拉唑治疗,以预防酸相关黏膜损伤,给药途径为口服或经鼻胃管给药。在第4天,静脉注射埃索美拉唑以评估口服生物利用度。在第1、3和4天对两组患者测定埃索美拉唑血清浓度,在第7天对SAH组患者测定该浓度。重度SAH患者的药物吸收严重受损。多数患者在出血后一周内肠内药物吸收仍无改善。

结论

SAH后药物吸收显著降低可能归因于肠道蠕动减弱和肠黏膜功能受损。临床医生应预计在重度SAH后至少七天内肠内给药的疗效会降低。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/102e/11698135/2a2df49b0099/ccm-53-e140-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/102e/11698135/82ed4cbc2f44/ccm-53-e140-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/102e/11698135/0fb0c7ba5295/ccm-53-e140-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/102e/11698135/2a2df49b0099/ccm-53-e140-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/102e/11698135/82ed4cbc2f44/ccm-53-e140-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/102e/11698135/0fb0c7ba5295/ccm-53-e140-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/102e/11698135/2a2df49b0099/ccm-53-e140-g003.jpg

相似文献

1
Intestinal Drug Absorption After Subarachnoid Hemorrhage and Elective Neurosurgery: Insights From Esomeprazole Pharmacokinetics.蛛网膜下腔出血和择期神经外科手术后的肠道药物吸收:埃索美拉唑药代动力学的启示
Crit Care Med. 2025 Jan 1;53(1):e140-e150. doi: 10.1097/CCM.0000000000006512. Epub 2024 Nov 20.
2
Oral Drug Absorption and Drug Disposition in Critically Ill Cardiac Patients.危重心血管疾病患者的口服药物吸收与药物处置
Pharmaceutics. 2023 Nov 7;15(11):2598. doi: 10.3390/pharmaceutics15112598.
3
Pharmacokinetics and Pharmacodynamics of a Fixed-Dose Combination of Esomeprazole and Magnesium Hydroxide Compared to the Enteric-Coated Esomeprazole.埃索美拉唑镁固定剂量复方制剂与肠溶衣埃索美拉唑的药代动力学和药效学比较
Clin Ther. 2024 Nov;46(11):870-876. doi: 10.1016/j.clinthera.2024.08.006. Epub 2024 Sep 16.
4
Effect of concomitant use of esomeprazole on levodopa pharmacokinetics and clinical symptoms in patients with Parkinson's disease.埃索美拉唑合用对帕金森病患者左旋多巴药代动力学和临床症状的影响。
J Neurol Sci. 2024 Oct 15;465:123202. doi: 10.1016/j.jns.2024.123202. Epub 2024 Aug 28.
5
Elective Treatment of Additional and Recurrent Aneurysms in Patients with a Previous Subarachnoid Hemorrhage: A Single-Center Analysis of Complications and Clinical Outcome.既往有蛛网膜下腔出血患者额外及复发性动脉瘤的择期治疗:并发症及临床结局的单中心分析
World Neurosurg. 2019 May;125:e1196-e1202. doi: 10.1016/j.wneu.2019.01.279. Epub 2019 Feb 19.
6
Esomeprazole administered through a nasogastric tube provides bioavailability similar to oral dosing.通过鼻胃管给药的埃索美拉唑的生物利用度与口服给药相似。
Aliment Pharmacol Ther. 2003 Sep 15;18(6):581-6. doi: 10.1046/j.1365-2036.2003.01667.x.
7
Oral esomeprazole in Japanese pediatric patients with gastric acid-related disease: Safety, efficacy, and pharmacokinetics.口服埃索美拉唑在日本患有胃酸相关疾病的儿科患者中的安全性、有效性和药代动力学。
Pediatr Int. 2019 Jan;61(1):87-95. doi: 10.1111/ped.13733.
8
Comparison of the pharmacokinetics and tolerability of HCP1004 (a fixed-dose combination of naproxen and esomeprazole strontium) and VIMOVO® (a marketed fixed-dose combination of naproxen and esomeprazole magnesium) in healthy volunteers.HCP1004(萘普生和埃索美拉唑锶的固定剂量组合)与VIMOVO®(市售的萘普生和埃索美拉唑镁固定剂量组合)在健康志愿者体内的药代动力学和耐受性比较。
Drug Des Devel Ther. 2015 Jul 31;9:4127-35. doi: 10.2147/DDDT.S86725. eCollection 2015.
9
The pharmacokinetics, pharmacodynamics and safety of oral doses of ilaprazole 10, 20 and 40 mg and esomeprazole 40 mg in healthy subjects: a randomised, open-label crossover study.健康受试者口服10毫克、20毫克和40毫克伊拉普唑以及40毫克埃索美拉唑的药代动力学、药效学和安全性:一项随机、开放标签交叉研究。
Aliment Pharmacol Ther. 2014 Sep;40(5):548-61. doi: 10.1111/apt.12860. Epub 2014 Jul 13.
10
Pharmacokinetics of esomeprazole after oral and intravenous administration of single and repeated doses to healthy subjects.在健康受试者中单次及重复口服和静脉注射埃索美拉唑后的药代动力学。
Eur J Clin Pharmacol. 2000 Dec;56(9-10):665-70. doi: 10.1007/s002280000206.

引用本文的文献

1
Pharmacotherapy variability and precision medicine in neurocritical care.神经重症监护中的药物治疗变异性与精准医学
Front Neurol. 2025 Jul 18;16:1630163. doi: 10.3389/fneur.2025.1630163. eCollection 2025.

本文引用的文献

1
Uncertain Answers - Proton-Pump Inhibition in the ICU.不确定的答案——重症监护病房中的质子泵抑制作用
N Engl J Med. 2024 Jul 4;391(1):78-79. doi: 10.1056/NEJMe2405782. Epub 2024 Jun 14.
2
Enhanced exclusive enteral nutrition delivery during the first 7 days is associated with decreased 28-day mortality in critically ill patients with normal lactate level: a post hoc analysis of a multicenter randomized trial.强化型肠内营养在发病 7 天内的早期给予与乳酸水平正常的危重症患者 28 天死亡率降低相关:一项多中心随机试验的事后分析。
Crit Care. 2024 Jan 20;28(1):26. doi: 10.1186/s13054-024-04813-6.
3
Oral Drug Absorption and Drug Disposition in Critically Ill Cardiac Patients.
危重心血管疾病患者的口服药物吸收与药物处置
Pharmaceutics. 2023 Nov 7;15(11):2598. doi: 10.3390/pharmaceutics15112598.
4
Considerations when administering medications enterally in the critically ill.在危重症患者中经肠给予药物时的注意事项。
Curr Opin Clin Nutr Metab Care. 2023 May 1;26(3):302-306. doi: 10.1097/MCO.0000000000000921. Epub 2023 Jan 31.
5
Formulation of Dosage Forms with Proton Pump Inhibitors: State of the Art, Challenges and Future Perspectives.质子泵抑制剂剂型的研发:现状、挑战与未来展望
Pharmaceutics. 2022 Sep 25;14(10):2043. doi: 10.3390/pharmaceutics14102043.
6
Bioavailability of Orally Administered Drugs in Critically Ill Patients.口服给药在危重症患者中的生物利用度。
J Pharm Pract. 2023 Aug;36(4):967-979. doi: 10.1177/08971900221100205. Epub 2022 May 6.
7
Current practice of stress ulcer prophylaxis in a surgical patient cohort in a German university hospital.德国一所大学附属医院外科患者群体中应激性溃疡预防的现行实践。
Langenbecks Arch Surg. 2021 Dec;406(8):2849-2859. doi: 10.1007/s00423-021-02325-3. Epub 2021 Sep 14.
8
Brain-gut axis dysfunction in the pathogenesis of traumatic brain injury.脑-肠轴功能障碍在创伤性脑损伤发病机制中的作用。
J Clin Invest. 2021 Jun 15;131(12). doi: 10.1172/JCI143777.
9
Stress-Related Gastrointestinal Bleeding in Patients with Aneurysmal Subarachnoid Hemorrhage: A Multicenter Retrospective Observational Study.动脉瘤性蛛网膜下腔出血患者的应激相关胃肠道出血:一项多中心回顾性观察研究。
Neurocrit Care. 2021 Aug;35(1):39-45. doi: 10.1007/s12028-020-01137-5. Epub 2020 Nov 4.
10
The study of intestinal absorption and biodistribution in vivo of proton pump inhibitors.质子泵抑制剂在体肠吸收和生物分布研究。
Eur J Pharm Biopharm. 2020 Apr;149:135-144. doi: 10.1016/j.ejpb.2020.01.015. Epub 2020 Jan 30.